Contrasting iRadimed Corporation (IRMD) & Apollo Endosurgery (APEN)

iRadimed Corporation (NASDAQ: IRMD) and Apollo Endosurgery (NASDAQ:APEN) are both small-cap medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their analyst recommendations, earnings, valuation, risk, institutional ownership, profitability and dividends.

Risk & Volatility

iRadimed Corporation has a beta of 1.47, meaning that its stock price is 47% more volatile than the S&P 500. Comparatively, Apollo Endosurgery has a beta of 0.17, meaning that its stock price is 83% less volatile than the S&P 500.

Insider and Institutional Ownership

14.1% of iRadimed Corporation shares are held by institutional investors. Comparatively, 8.9% of Apollo Endosurgery shares are held by institutional investors. 60.1% of iRadimed Corporation shares are held by company insiders. Comparatively, 74.2% of Apollo Endosurgery shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.


This table compares iRadimed Corporation and Apollo Endosurgery’s net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
iRadimed Corporation 11.61% 8.98% 7.69%
Apollo Endosurgery -62.31% -113.42% -43.00%

Analyst Recommendations

This is a breakdown of recent recommendations for iRadimed Corporation and Apollo Endosurgery, as provided by MarketBeat.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
iRadimed Corporation 0 0 1 0 3.00
Apollo Endosurgery 0 0 3 0 3.00

iRadimed Corporation currently has a consensus price target of $12.00, suggesting a potential downside of 5.51%. Apollo Endosurgery has a consensus price target of $11.00, suggesting a potential upside of 166.34%. Given Apollo Endosurgery’s higher possible upside, analysts plainly believe Apollo Endosurgery is more favorable than iRadimed Corporation.

Earnings and Valuation

This table compares iRadimed Corporation and Apollo Endosurgery’s revenue, earnings per share and valuation.

Gross Revenue Price/Sales Ratio EBITDA Earnings Per Share Price/Earnings Ratio
iRadimed Corporation $24.35 million 5.52 $4.51 million $0.24 52.92
Apollo Endosurgery $63.01 million 1.13 -$10.53 million ($36.74) -0.11

iRadimed Corporation has higher revenue, but lower earnings than Apollo Endosurgery. Apollo Endosurgery is trading at a lower price-to-earnings ratio than iRadimed Corporation, indicating that it is currently the more affordable of the two stocks.


iRadimed Corporation beats Apollo Endosurgery on 8 of the 12 factors compared between the two stocks.

About iRadimed Corporation

IRADIMED CORPORATION (IRADIMED) develops, manufactures, markets and distributes Magnetic Resonance Imaging (MRI) compatible products, and provides non-magnetic intravenous (IV) infusion pump systems. The Company operates through development, manufacture and sale of MRI compatible products and IV infusion pump systems for use by hospitals and acute care facilities during MRI procedures segment. Its MRidium MRI compatible IV infusion pump system has been designed with a non-magnetic ultrasonic motor, non-ferrous part and other features in order to deliver anesthesia and other IV fluids during various MRI procedures. MRI compatible IV infusion pump system includes the 3860+ MRI compatible IV infusion pump, single-use IV tubing sets, a non-magnetic pole and a lithium battery. In addition, it offers optional upgrade systems, including the 3865 Remote Display/Control, 3861 Side Car, Dose Error Reduction System (DERS) and SpO2 monitor.

About Apollo Endosurgery

Apollo Endosurgery, Inc., formerly Lpath, Inc., is a medical device company. The Company is focused on less invasive therapies for the treatment of obesity, as well as other gastrointestinal disorders. The Company’s device-based therapies are an alternative to invasive surgical procedures. The Company offers products in over 80 countries. The Company’s products include ORBERA, LAP-BAND and OverStitch. The Company’s product, ORBERA, is a gastric balloon. The ORBERA Intragastric Balloon System is a weight loss aid for adults suffering from obesity. The LAP-BAND System is a minimally invasive procedure that offers weight loss. The LAP-BAND System is indicated for weight reduction for patients with obesity. The OverStitch Endoscopic Suturing System enables advanced endoscopic surgery by allowing physicians to place full-thickness sutures through a flexible endoscope. OverStitch offers solutions for defects in both the upper and lower gastrointestinal tract.

Receive News & Ratings for iRadimed Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for iRadimed Corporation and related companies with's FREE daily email newsletter.

Leave a Reply